Clinically, the FDA approval of semaglutide (Wegovy ) marks a significant advance in obesity therapy, demonstrating not only substantial weight reduction but also reduced cardiovascular risk in high-risk populations [242]
Yes, newer guidelines and easier dosing may encourage earlier use to improve long-term outcomes
les borrlioses peuvent conduire des complications neurologiques : mningo-encphalites (chez moins de 5% des patients avec signes neurologiques), ou encore vasculite crbrale
Hart EC, Joyner MJ, Wallin BG, Johnson CP, Curry TB, Eisenach JH
Myth: You need extensive thyroid testing before starting GLP-1 medications
So it makes sense that there's been a rise in so-called 'natural GLP-1 supplements,' which promise (or heavily imply) that theyll deliver similar results that youd get from an injectable GLP-1 medication only in a more accessible, far less expensive oral supplement